Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz
Phase 3
Recruiting
- Conditions
- Ischemic Stroke
- Interventions
- Drug: Neu2000KWL groupDrug: Placebo group
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- GNT Pharma
- Target Recruit Count
- 496
- Registration Number
- NCT05041010
- Locations
- π°π·
Daejeon Eulji Medical Center, Eulji University, Daejeon, Korea, Republic of
π°π·Chonnam National University Hospital, Gwangju, Korea, Republic of
π°π·Dong-A University Hospital, Busan, Korea, Republic of
Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients
Phase 2
- Conditions
- Cardiac Arrest
- Interventions
- Drug: Neu2000KWL High-dose groupDrug: Neu2000KWL Low-dose groupDrug: Placebo
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- GNT Pharma
- Target Recruit Count
- 150
- Registration Number
- NCT03651557
- Locations
- π°π·
Kyungpook National University Hospital, Daegu, Korea, Korea, Republic of
π°π·Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of
π°π·Pusan National University Hospital, Busan, Korea, Republic of
Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)
Phase 2
- Conditions
- Ischemic Stroke
- Interventions
- Drug: Neu2000KWL Low-does groupDrug: PlaceboDrug: Neu2000KWL High-does group
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GNT Pharma
- Target Recruit Count
- 210
- Registration Number
- NCT02831088
- Locations
- π°π·
Chungbuk National University Hospital, Cheongju, Korea, Republic of
π°π·Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
π°π·Chosun University Hospital, Gwangju, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath